In contrast, a phase II study treating liposarcoma patients withrosiglitazone did not significantly improve clinical outcome [66] and sofar no beneficial effects of PPARγ ligands havebeen observed in trials for breast or colon cancer patients [35]. This evidence concerns the gene PPARG and liposarcoma.